C4U Corporation (“C4U”) is pleased to announce that a patent for the invention titled “Method for Producing Cas3 Protein” was issued on December 24, 2025, as European Patent No. 4303310.
This invention relates to a method for producing Cas3 protein, one of the key protein components of the CRISPR-Cas3 genome editing system. This method enables the high-purity and high-yield production of recombinant proteins while maintaining their biological activity. As proteins are a vital component of the CRISPR-Cas3 modality, this technology will be applied to both diagnostic and genome editing applications.
C4U will continue to strengthen its intellectual property portfolio for CRISPR-Cas3 technology worldwide and accelerate its application across a wide range of sectors, including the pharmaceutical field.
About C4U
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by the University of Osaka for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape. https://www.crispr4u.jp/en/
Contact
C4U Corporation
Address：Yamadaoka 2-8, Suita, Osaka 565-0871, Japan
E-mail：info@crispr4u.com
